According to Zhitong Finance App News, Oriental Biotech (688298.SH) disclosed its 2026 semi-annual report. During the reporting period, the company achieved operating income of 464 million yuan, an increase of 15.15%; net profit loss attributable to shareholders of listed companies was 222 million yuan, an increase over the previous year; net profit loss after deducting non-recurring profit and loss was 238 million yuan, an increase over the previous year; and basic earnings per share were 1.16 yuan.

According to Zhitong Finance App News, Oriental Biotech (688298.SH) disclosed its 2026 semi-annual report. During the reporting period, the company achieved operating income of 464 million yuan, an increase of 15.15%; net profit loss attributable to shareholders of listed companies was 222 million yuan, an increase over the previous year; net profit loss after deducting non-recurring profit and loss was 238 million yuan, an increase over the previous year; and basic earnings per share were 1.16 yuan.